阿舒瑞韦-达卡他韦治疗患者中拉替拉韦的药代动力学
Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
作者信息
Barrail-Tran Aurélie, Vincent Corine, Furlan Valérie, Rosa Isabelle, Rosenthal Eric, Cheret Antoine, Molina Jean-Michel, Taburet Anne-Marie, Piroth Lionel
机构信息
AP-HP, Hôpital Bicêtre, Pharmacie Clinique, Le Kremlin Bicêtre, France Université Paris Sud, INSERM UMR 1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France
INSERM SC10-US019, Villejuif, France.
出版信息
Antimicrob Agents Chemother. 2015 Dec;59(12):7903-5. doi: 10.1128/AAC.01603-15. Epub 2015 Oct 5.
Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon-ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.
在法国国家艾滋病研究机构（ANRS）HC30 QUADRIH研究纳入的20名患者中，于添加抗丙型肝炎病毒（抗HCV）四联疗法（包括聚乙二醇化干扰素-利巴韦林以及阿舒瑞韦加拉米夫定）之前及之后，对拉替拉韦的药代动力学进行了研究。无论在抗HCV治疗期间还是治疗期外给药，拉替拉韦的药代动力学参数均保持不变。此外，拉替拉韦、阿舒瑞韦和达卡他韦的浓度不受肝硬化影响。这些数据表明，在人类免疫缺陷病毒（HIV）-HCV合并感染患者中，无论是否患有肝硬化，阿舒瑞韦和达卡他韦均可与拉替拉韦安全联用。
Zotero 插件